75 related articles for article (PubMed ID: 312848)
1. Study on the turnover of the receptor for the third component of complement on human lymphoid cells.
Rosso di San Secondo VE; Meroni PL; Fortis C; Tedesco F
J Immunol; 1979 May; 122(5):1658-62. PubMed ID: 312848
[TBL] [Abstract][Full Text] [Related]
2. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
[TBL] [Abstract][Full Text] [Related]
3. In vitro complement activation by rabbit lymphocytes and thymocytes in autologous serum.
Wilson AB; Lachmann PJ; Coombs RR
Immunology; 1979 May; 37(1):25-34. PubMed ID: 112041
[TBL] [Abstract][Full Text] [Related]
4. A simple rosette assay for demonstration of complement receptor sites using complement-coated zymosan beads.
Huber Ch; Wigzell H
Eur J Immunol; 1976 Jun; 5(6):432-5. PubMed ID: 1086242
[TBL] [Abstract][Full Text] [Related]
5. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of lymphocyte Fc alpha receptor in selective IgA deficiency and IgA nephropathy.
Adachi M; Yodoi J; Masuda T; Takatsuki K; Uchino H
J Immunol; 1983 Sep; 131(3):1246-51. PubMed ID: 6224855
[TBL] [Abstract][Full Text] [Related]
7. The detection of membrane-associated complement components (C 3 and C 4) on circulating human normal and leukemic leukocytes and on cultured cells with monkey erythrocytes.
Burns GF; Cawley JC
Eur J Immunol; 1979 Oct; 9(10):791-6. PubMed ID: 118035
[TBL] [Abstract][Full Text] [Related]
8. Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells.
Schmitt M; Mussel HH; Dierich MP
J Immunol; 1981 May; 126(5):2042-7. PubMed ID: 7217681
[TBL] [Abstract][Full Text] [Related]
9. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
Marquart HV; Svehag SE; Leslie RG
J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
[TBL] [Abstract][Full Text] [Related]
10. Surface properties of LDL-binding lymphocytes in human peripheral blood.
Hiramatsu K; Sakai H; Endoh M; Arimori S
Immunology; 1980 Mar; 39(3):311-6. PubMed ID: 6969214
[TBL] [Abstract][Full Text] [Related]
11. Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.
Praz F; Lesavre P
J Immunol; 1983 Sep; 131(3):1396-9. PubMed ID: 6604099
[TBL] [Abstract][Full Text] [Related]
12. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
13. Failure to block lymphocyte Fc receptor with anti-B lymphocyte sera (anti-DRW) in man.
Soulillou JP; Peyrat MA
Immunology; 1979 Mar; 36(3):519-25. PubMed ID: 312261
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of phytohaemagglutinin-induced autorosette formation of human peripheral blood lymphocytes by RNA or protein synthesis inhibitor.
Hyodo S; Kishi T; Kittaka E; Suzawa T; Tanabe A; Tanaka Y; Sakano T; Usui T
Clin Exp Immunol; 1983 Jul; 53(1):140-4. PubMed ID: 6191894
[TBL] [Abstract][Full Text] [Related]
15. Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans.
Einstein LP; Hansen PJ; Ballow M; Davis AE; Davis JS; Alper CA; Rosen FS; Colten HR
J Clin Invest; 1977 Nov; 60(5):963-9. PubMed ID: 332718
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin-bearing and complement-receptor lymphocytes constitute the same population in human peripheral blood.
Ehlenberger AG; McWilliams M; Phillips-Quagliata JM; Lamm ME; Nussenzweig V
J Clin Invest; 1976 Jan; 57(1):53-6. PubMed ID: 1081992
[TBL] [Abstract][Full Text] [Related]
17. Native C3 does not bind to the C3b receptor (CR1) of human blood B lymphocytes or alter immunoglobulin synthesis.
Berger M; Fleisher TA
J Immunol; 1983 Mar; 130(3):1021-3. PubMed ID: 6600466
[TBL] [Abstract][Full Text] [Related]
18. Identity of C3- and C5-receptors on lymphoid cells.
Landen B; Dierich MP
J Immunol; 1979 Mar; 122(3):1015-7. PubMed ID: 448068
[TBL] [Abstract][Full Text] [Related]
19. In vitro synthesis of some complement components (C1q, C3 and C4) by lymphoid tissues and circulating leucocytes in man.
Lai A Fat RF; van Furth R
Immunology; 1975 Feb; 28(2):359-68. PubMed ID: 804438
[TBL] [Abstract][Full Text] [Related]
20. Biosynthesis and secretion of the third component of complement by human endothelial cells in vitro.
Ueki A; Sai T; Oka H; Tabata M; Hosokawa K; Mochizuki Y
Immunology; 1987 May; 61(1):11-4. PubMed ID: 3108140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
